Plasma Atrial Natriuretic Peptide in Essential Hypertension after Treatment with Irbesartan

Kotridis, P.; Kokkas, B.; Karamouzis, Michalis V.; Sakadamis, G.; Kanonidis, Ioannis; Dadous, George; Karantona, C.; Gouli, Olga; Karadoumanis, J.; Papadopoulos, Pavlos; Papadopoulos, C.

doi:10.1080/08037050211263

Cited by 11 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The natriuretic peptides were significantly reduced by eprosartan during the entire study day. This contrasts with other reports on the effect of AT1 blockade on concentrations of ANP, as ANP increased after treatment with irbesartan for 30 days in patients with essential hypertension [37] and also after administration of candesartan for 8 weeks in the rat [38]. The reason for this discrepancy is unclear, but could be related to fact that we evaluated only the very short term effect of eprosartan during sodium restriction.…”

Section: Discussioncontrasting

confidence: 83%

Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans

Vase

Lauridsen

Bech

et al. 2008

Brit J Clinical Pharma

View full text Add to dashboard Cite

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• A sympatho-inhibitory effect of ACE-inhibitors and AT1 receptor antagonists has been widely demonstrated in animal models, but in humans this effect tends only to be present during chronic treatment in conditions with pre-existing high levels of sympathetic activity.• Sodium restriction increases renal sympathetic nerve activity and the activity of the renin-angiotensin system and may be a favourable condition to demonstrate sympatho-inhibition as a short-term effect of the AT1 receptor antagonist eprosartan in healthy humans. WHAT THIS STUDY ADDS• Results from our study indicate that during sodium restriction eprosartan has a small inhibitory effect on nonbaroreflex mediated activation of the sympathetic nervous system. • During arterial baroreflex mediated activation of the sympathetic nervous system this effect is, however, completely overruled by an increased sensitivity of the arterial baroreflex. AIMSTo test the hypothesis that eprosartan inhibits both nonbaroreflex and arterial baroreflex mediated activation of the sympathetic nervous system, assessed by renal tubular function, systemic haemodynamics and vasoactive hormones, in sodium restricted healthy humans. METHODSThe effect of eprosartan on urinary sodium, lithium and water excretion, heart rate (HR), blood pressure and vasoactive hormones was measured before, during and after a cold pressor test (CPT) and sodium nitroprusside (SNP) infusion in a randomized, placebo controlled, double-blind, crossover study in 17 healthy subjects. Glomerular filtration rate and renal tubular function were determined by a continuous infusion clearance technique and vasoactive hormones by radioimmunoassays. RESULTSEprosartan attenuated the impact of the CPT on HR (mean difference from placebo (95% confidence interval) (3.9 (0.7, 7.0) min) and mean arterial pressure (MAP) (4.7 (0.3, 9.2) mmHg), but no effect of eprosartan was observed on the impact of the CPT on renal tubular function. During a SNP induced reduction in MAP of 10 mmHg eprosartan decreased fractional excretions of sodium (0.46 (0.14, 0.76)%) and lithium (5.1 (2.5, 7.6)%) and tended to increase HR (4.1 (-0.26, 8.4) min -1 ) and plasma concentrations of norepinephrine (33.8 (-5.8, 72.1) pg ml CONCLUSIONSThese findings suggest that during mild sodium restriction eprosartan has a small inhibitory effect on nonbaroreflex mediated activation of the sympathetic nervous system. During arterial baroreflex mediated activation of the sympathetic nervous system this effect is, however, completely overruled by an increased sensitivity of the arterial baroreflex.

show abstract

Section: Discussioncontrasting

confidence: 83%

Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans

Vase

Lauridsen

Bech

et al. 2008

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…This is a very important finding because the relation between the plasma levels of ANP and the systolic blood pressure rate reflects mechanisms of the antihypertensive action of the drug after a medium term treatment. Nebivolol follows the same rule as~ adrenergic blockers of older generation as well as antihypertensive drugs of other classes (3)(4)(5)(6)(8)(9)(10)(11)(12)(13)(14)(15).…”

Section: Discussionmentioning

confidence: 99%

Nebivolol Increases Atrial Natriuretic Peptide/Systolic Blood Pressure Ratio in Hypertensive Patients

et al. 2008

View full text Add to dashboard Cite

The aim of this study is to evaluate the medium term treatment effects of the beta-blocker nebivolol on the endogenous anti-hypertensive and anti-inflammatory agent Atrial Natriuretic Peptide (ANP) plasma levels in patients with moderate uncomplicated essential hypertension. The drug was given orally for 30 days to 25 patients. The daily dose was 5 mg once every morning. Quantitative determination of ANP was made by Radioimmunoassay (RIA). At the end of this clinical trial, plasma ANP levels showed a statistically non significant tendency to increase by 10.99% while both systolic (SBP) and diastolic (DBP) blood pressure as well as the diameters ofthe left cardiac cavities showed a statistically significant decrease. What was interesting was the fact that there was a statistically significant increase of 44.7% in the ratio ANP/SBP following the reduction of arterial blood pressure. This increase was the most important and essential finding as it indicated a real increase of ANP plasma levels. This result was obtained even though pressure and afterload, the homologous mechanical stimulatory parameters for ANP secretion, of the left cavities were diminished. These findings provide strong indications which were supported by several previous trials, that the increase in plasma ANP following the administration of beta-adrenergic blockers to hypertensive patients was a primary effect of beta blockade and not a mechanical one secondary to a negative inotropic action on the left ventricle. This primary action contributed to the anti-hypertensive effect of nebivolol during this trial.It is known that the short-term effect of antihypertensive drugs is due to their action on cardiac output and/or peripheral resistance. However, their long-term effect is due to changes in the pressure/natriuresis relationship. No conventional hemodynamic effect can provide a satisfactory explanation for the chronic long-term antihypertensive efficacy of p-adrenergic blockers.Thus, it is quite reasonable to try to explain the effects of the above drugs on the arterial pressure by evaluating their action on factors that control pressure-natriuresis. Such a factor is Atrial Natriuretic Peptide (ANP) which also possesses antiinflammatory properties (1). Furthermore, the links between inflammation and cardiovascular diseases, especially hypertension, are well documented (2).

show abstract

“…Through a literature search and analysis of the remaining 31 DTIs, we identified three novel DTIs: Kim et al [ 43 ] showed that the administration of Triamcinolone significantly reduced the expression level of the leukotriene C4 synthase gene (LTC4S). This is a potential DTI identified by GSRF-DTI, but the interaction was not found in DrugBank Kotridis et al [ 44 ] indicated that Irbesartan exert part of their antihypertensive action by increasing atrial natriuretic peptide plasma (NPR1) levels. This is a potential DTI identified by GSRF-DTI Turrell et al [ 45 ] investigated the role of ATP-sensitive inward rectifier potassium channel 11 (KCNJ11) in the preconditioning of phenylephrine in isolated ventricular myocytes.…”

Section: Case Studymentioning

confidence: 99%

“…Kotridis et al [ 44 ] indicated that Irbesartan exert part of their antihypertensive action by increasing atrial natriuretic peptide plasma (NPR1) levels. This is a potential DTI identified by GSRF-DTI…”

Section: Case Studymentioning

confidence: 99%

GSRF-DTI: a framework for drug-target interaction prediction based on a drug-target pair network and representation learning on a large graph

Zhu,

Ning,

Zhang

et al. 2024

BMC Biol

View full text Add to dashboard Cite

Background Identification of potential drug-target interactions (DTIs) with high accuracy is a key step in drug discovery and repositioning, especially concerning specific drug targets. Traditional experimental methods for identifying the DTIs are arduous, time-intensive, and financially burdensome. In addition, robust computational methods have been developed for predicting the DTIs and are widely applied in drug discovery research. However, advancing more precise algorithms for predicting DTIs is essential to meet the stringent standards demanded by drug discovery. Results We proposed a novel method called GSRF-DTI, which integrates networks with a deep learning algorithm to identify DTIs. Firstly, GSRF-DTI learned the embedding representation of drugs and targets by integrating multiple drug association information and target association information, respectively. Then, GSRF-DTI considered the influence of drug-target pair (DTP) association on DTI prediction to construct a drug-target pair network (DTP-NET). Next, we utilized GraphSAGE on DTP-NET to learn the potential features of the network and applied random forest (RF) to predict the DTIs. Furthermore, we conducted ablation experiments to validate the necessity of integrating different types of network features for identifying DTIs. It is worth noting that GSRF-DTI proposed three novel DTIs. Conclusions GSRF-DTI not only considered the influence of the interaction relationship between drug and target but also considered the impact of DTP association relationship on DTI prediction. We initially use GraphSAGE to aggregate the neighbor information of nodes for better identification. Experimental analysis on Luo’s dataset and the newly constructed dataset revealed that the GSRF-DTI framework outperformed several state-of-the-art methods significantly.

show abstract

Plasma Atrial Natriuretic Peptide in Essential Hypertension after Treatment with Irbesartan

Cited by 11 publications

References 17 publications

Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans

Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans

Nebivolol Increases Atrial Natriuretic Peptide/Systolic Blood Pressure Ratio in Hypertensive Patients

GSRF-DTI: a framework for drug-target interaction prediction based on a drug-target pair network and representation learning on a large graph

Contact Info

Product

Resources

About